Skip to main content
INVION LIMITED logo

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2010-05-16 Capital/Financing Update
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Letter to Ineligible Shareholders 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is a letter dated 17 May 2010 from the company secretary of CBio Limited to shareholders regarding a Share Purchase Plan (SPP). It explains eligibility criteria for participation in the SPP and provides general information about the company and its product pipeline. There are no financial statements, detailed financial data, or regulatory filings such as annual or interim reports. The document is an announcement about a capital raising opportunity (share purchase plan) and is informational in nature. Given the content focuses on a financing activity (share purchase plan) and is not a full report or regulatory filing, the appropriate classification is Capital/Financing Update (CAP). The document length is short but contains substantive information about the financing activity, not just a notice or report publication announcement.
2010-05-16 English
SPP Rules 13 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is a detailed Share Purchase Plan (SPP) offering shareholders the opportunity to purchase additional shares in the company at a discounted price. It includes key dates, offer details, eligibility criteria, application instructions, and terms and conditions related to the share issuance. The content focuses on fundraising through issuing new shares to existing shareholders, which is a capital raising activity. There is no indication that this is a full financial report, earnings release, or regulatory filing unrelated to capital changes. The document is not a brief announcement but a full explanatory offer document. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it relates to company fundraising and capital structure changes through a share purchase plan.
2010-05-16 English
Clinical Trial Update 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a short announcement dated 14 May 2010 from CBio Limited to the ASX Company Announcements Office. It provides an update on the dosing of the first European patient in a phase IIa clinical trial for a drug candidate. The content is focused on clinical trial progress and recruitment status, with no financial data, regulatory filings, or detailed report content. The document length is only 2389 characters, which is quite short and does not contain financial statements or detailed analysis. It is clearly an announcement of a clinical trial update rather than a financial report or regulatory filing. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2010-05-13 English
Notice of General Meeting/Proxy Form 7 pages ?Kb
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Notice of General Meeting for CBio Limited, including an Explanatory Memorandum and Proxy Form. It details resolutions for shareholder approval related to prior share and share option issues, with references to ASX Listing Rules 7.4 and 7.5. The content focuses on seeking shareholder approval for prior share issues and options, providing technical information required by the ASX, and instructions for voting and proxy appointment. There are no financial statements or detailed financial performance data, nor is this a transcript, audit report, or earnings release. The document is clearly a solicitation for shareholder votes at a general meeting, including proxy materials and explanatory notes. This fits the definition of Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings.
2010-05-13 English
Shareholder Newsletter 2 pages ?Kb
Interim / Quarterly Report Classification · 95% confidence The document is titled 'QUARTERLY INVESTOR UPDATE: Q2 2010' and contains detailed operational updates, clinical trial progress, intellectual property developments, market updates, regulatory information, and business news related to the company's activities during the quarter. It includes substantive financial and operational data for a period shorter than a full fiscal year (Q2 2010). There is no indication that this is a brief announcement or a certification letter. The content aligns with a comprehensive interim or quarterly report rather than a simple earnings release or investor presentation. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2010
2010-04-21 English
Appendix 3B- Amended 10 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and contains detailed information about the issuance of new securities, including ordinary shares and share options, their terms, expiry dates, issue prices, and escrow details. It also includes a correction notice regarding the expiry date of share options. The document references ASX rules and is structured as a formal announcement to the ASX Limited. Appendix 3B is a well-known form used in Australian securities markets for announcing new issues of securities. The content is focused on the issuance and quotation of new shares and options, which aligns with announcements about share issues or capital changes. There is no financial performance data, management discussion, or audit information present. The document is not a report but an official announcement of a new share issue and related securities. Therefore, the correct classification is 'Share Issue/Capital Change' (SHA). The document length and detail support a high confidence in this classification.
2010-04-13 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.